Bexxar iodine-131 radiolabeled monoclonal antibody targeted to the CD20 antigen on B cells data

CLTR announced preliminary findings with Bexxar, showing >50 percent shrinkage of tumor in all treated patients. As reported

Read the full 186 word article

How to gain access

Continue reading with a
two-week free trial.